WO2012047656A8 - Lipid a analog compositions - Google Patents

Lipid a analog compositions Download PDF

Info

Publication number
WO2012047656A8
WO2012047656A8 PCT/US2011/053472 US2011053472W WO2012047656A8 WO 2012047656 A8 WO2012047656 A8 WO 2012047656A8 US 2011053472 W US2011053472 W US 2011053472W WO 2012047656 A8 WO2012047656 A8 WO 2012047656A8
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
compositions
analog compositions
analog
component
Prior art date
Application number
PCT/US2011/053472
Other languages
French (fr)
Other versions
WO2012047656A1 (en
Inventor
Kishor M. Wasan
Jacklyn G. Fleischer
Daniel P. Rossignol
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of WO2012047656A1 publication Critical patent/WO2012047656A1/en
Publication of WO2012047656A8 publication Critical patent/WO2012047656A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided are compositions compirsing a Lipd A analog, e.g., a compound of formula (I): or a pharmaceutically acceptable salt thereof, and an anti-sequestration component, such as a component of LDL. Also provided are methods for treating disorders, e.g., sepsis, using such compositions.
PCT/US2011/053472 2010-09-27 2011-09-27 Lipid a analog compositions WO2012047656A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38673610P 2010-09-27 2010-09-27
US61/386,736 2010-09-27

Publications (2)

Publication Number Publication Date
WO2012047656A1 WO2012047656A1 (en) 2012-04-12
WO2012047656A8 true WO2012047656A8 (en) 2012-06-14

Family

ID=45928082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053472 WO2012047656A1 (en) 2010-09-27 2011-09-27 Lipid a analog compositions

Country Status (1)

Country Link
WO (1) WO2012047656A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3985118A1 (en) 2013-11-22 2022-04-20 MiNA Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
CA3075219A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
WO2020129826A1 (en) * 2018-12-17 2020-06-25 Eisai R&D Management Co., Ltd. Formulation comprising liposomes
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
TW202305133A (en) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna compositions and methods of use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis

Also Published As

Publication number Publication date
WO2012047656A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2012047656A8 (en) Lipid a analog compositions
WO2014100764A3 (en) Methods of inhibiting prmt5
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
WO2013142817A3 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
MX2016006336A (en) Pyrazolopyrimidine compounds.
WO2013003298A3 (en) Inhibitors of pde10
WO2013055684A8 (en) Rasagiline citramide
AU2012213775A8 (en) 7-azaindole derivatives
WO2012042371A3 (en) Pharmaceutical composition
WO2013009527A3 (en) Factor ixa inhibitors
WO2013040286A3 (en) Pharmaceutical compositions
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2010138598A3 (en) Lxr modulators
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
WO2010129918A8 (en) Triptolide prodrugs
WO2011143503A3 (en) Tetracycline compositions
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
WO2011163636A3 (en) Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2012061785A3 (en) Ice inhibiting compounds and uses thereof
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2012172438A3 (en) Compositions and methods for modulating a kinase
LT2625163T (en) Method for the preparation of (3s,3s`) 4,4`-disulfanediylbis (3-aminobutane 1-sulfonic acid)
WO2013062966A3 (en) Methanol derivatives as trpv3 modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831300

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11831300

Country of ref document: EP

Kind code of ref document: A1